Phase II Trial of Post-operative or Definitive Concurrent Radiation and Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2018
Price : $35 *
At a glance
- Drugs Cetuximab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 09 Nov 2018 Planned primary completion date changed from 1 Apr 2017 to 1 Jan 2019.
- 09 Nov 2018 Planned End Date changed from 1 Oct 2021 to 1 Oct 2022.
- 09 Nov 2018 Status changed from recruiting to active, no longer recruiting.